3rd spinal cord injury patient has surgery with InVivo's Neuro-Spinal Scaffold — 5 key notes

Laura Dyrda -   Print  |

The third patient has been enrolled in InVivo Therapeutic's Neuro-Spinal Scaffold clinical trial for spinal cord injury treatment.

Here are five key notes on the patient:


1. The patient will participate in the trial after sustaining acute spinal cord injury. Treatment was at Carolinas Medical Center, which is part of Carolinas HealthCare System.


2. The co-principal investigators at the site are Dom Coric, MD, of Carolina Neurosurgery and Spine Associates and Chief of Neurosurgery at Carolinas Medical Center; and William Bockenek, MD, chief medical officer at Carolinas Rehabilitation.


3. Dr. Coric and his colleague Mark Smith, MD, performed the surgery to implant Neuro-Spinal Scaffold for the third time in a patient with acute spinal cord injury.


4. The surgery occurred three-and-a-half days after injury.


5. The Neuro-Spinal Scaffold is FDA-approved for the investigational device exemption pilot study for five subjects. Following the initial trial, InVivo plans to conduct a pivotal study for FDA approval before moving on to commercialization under a Humanitarian Device Exemption.


"The implantation procedure went smoothly and the patient is doing very well," said Dr. Coric. "It has been rewarding to be involved in this clinical study, and I look forward to following the patient's progress."


More articles on orthopedic devices:
Mazor appoints Chad Zaring vice president of national accounts—5 key notes
Bacterin launches ArthroFuse: 4 quick facts
Is the Zimmer-Biomet closed merger finally around the corner? 5 things to know

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers